Artivion

Artivion, Inc. focuses on developing solutions that address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment provides cardiac and vascular tissue preservation services. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Artivion reports strong revenue growth, FDA engagement on trial data

Artivion's Q4 2022 performance reflects solid revenue growth and improved margins, despite trial setbacks.
The company's strategic focus on innovation and expansion presents long-term growth opportunities.
Challenges with trial outcomes and FDA discussions highlight regulatory complexities impacting approvals.
Engagement with the FDA to address trial data issues could pave the way for future product launches.

Artivion (AORT) reports strong Q1 performance and eyes FDA approvals for growth

Artivion's Q1 performance showcases steady growth and strategic focus on product approvals and market expansion. Despite challenges in margins and debt, the company's outlook remains optimistic, with raised guidance for revenue and EBITDA. Key opportunities lie in FDA approvals and targeted growth in emerging markets.

Artivion excels in Q2 2023, raises revenue guidance for growth

Artivion's Q2 2023 performance reflects robust revenue growth, improved profitability, and enhanced cash position, setting the stage for future success.
The company's focus on innovation, clinical trials progress, and raised revenue guidance underscore its commitment to sustained growth and market leadership.
With strong financial fundamentals and a positive outlook for revenue and EBITDA, Artivion is well-positioned to capitalize on market opportunities and drive shareholder value.
Artivion's strategic initiatives and product advancements position it for continued success, supported by a solid financial foundation and a focus on operational efficiency.

Artivion reports robust Q3 results, eyes double-digit growth in 2024

Artivion's Q3 2023 performance was strong, with revenue growth and positive clinical data driving optimism for future growth and market share gains.
While challenges exist in balancing profitability and growth, the company's focus on top-line revenue growth and market expansion presents opportunities for sustained success.
With a clear roadmap for continued momentum in 2024, Artivion aims for double-digit revenue growth and $75 million EBITDA, supported by product innovation and market strategies.

Artivion reports robust 2023 growth, eyes market expansion and innovation

Artivion's strong financial performance in 2023, coupled with positive clinical trial results, sets a solid foundation for future growth.
The company's focus on innovation, market expansion, and optimized portfolio positions it well for continued success in 2024 and beyond.
Challenges with hemiarch procedures and the DANE connection underscore the importance of ongoing research and development efforts.
With a strategic approach to market growth and product development, Artivion is poised to capitalize on emerging opportunities and drive value for stakeholders.

Artivion reports robust Q1 performance, eyes growth in key markets

Artivion's Q1 2024 performance reflects strong revenue and EBITDA growth, driven by key product segments and regions. Positive clinical trial results and raised revenue guidance indicate a promising outlook. Challenges include regional revenue fluctuations and cash flow concerns.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

DexCom

Edwards Lifesciences

Shockwave Medical

Transmedics Group Inc

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.

Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?

ATLANTA , March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m.

Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a Bet

Artivion, Inc. (AORT) Q4 2023 Earnings Call Transcript

Artivion (AORT) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to earnings of $0.10 per share a year ago.

Artivion (AORT) Surpasses Q4 Earnings and Revenue Estimates

Fourth Quarter and Recent Business Highlights: Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis and 15% on a non-GAAP constant currency basis Achieved revenue of $354.0 million for the full year of 2023 versus $313.8 million for the full year of 2022, an increase of 13% on a GAAP basis and 12% on a non-GAAP constant currency basis Net loss was ($4.0) million or ($0.10) per fully diluted share and non-GAAP net income was $4.6 million or $0.11 per fully diluted share in the fourth quarter of 2023 Non-GAAP adjusted EBITDA increased 40% to $15.3 million in the fourth quarter of 2023 compared to $11.0 million in the fourth quarter of 2022. For the full year adjusted EBITDA increased 29.5% to $53.8 million Generated $11.4 million of free cash flow for the full year of 2023 Closed non-dilutive credit agreement for $350.0 million of senior secured, interest-only, credit facilities with 6-year maturities Completed enrollment of the AMDS PERSEVERE clinical trial and presented positive results of the full IDE cohort at the STS Annual Meeting demonstrating a significant reduction of all-cause mortality and primary major adverse events (MAEs) at 30-days following AMDS implantation Appointed Lance A.

Artivion Reports Fourth Quarter and Full Year 2023 Financial Results

ATLANTA , Feb. 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2023 financial results will be released on Thursday, February 15, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results

Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events (MAEs) at 30 days with use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion 72% Reduction in All-Cause Mortality and 52% Reduction in Primary Major MAEs when Compared to Current Standard of Care Hemi-arch Procedure ATLANTA , Jan. 29, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of results from the AMDS PERSEVERE clinical trial in a Late-Breaking Science presentation at the 60th Annual Meeting of the Society of Thoracic Surgeons in San Antonio, Texas. The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at 30-days following AMDS implantation.

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting

Ares Management

Non-Dilutive Financing Provides Comprehensive Solution to Address Debt Maturities  and Provide Flexibility to Further Optimize Capital Structure ATLANTA , Jan. 18, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of a comprehensive, non- dilutive definitive credit agreement with Ares Management Credit funds for $350 million of senior secured, interest-only, credit facilities with 6-year maturities. The credit facilities include an initial $190 million term loan, a $60 million revolving credit facility, and an additional $100 million in unfunded delayed draw term loan commitments that may be drawn to refinance the Company's convertible bonds at any time on or prior to the maturity of the convertible bonds, subject to customary conditions.

Artivion Obtains $350 Million in Senior Secured Credit Facilities

Reports of various elected U.S. officials making significant, conveniently timed trades are not, unfortunately, rare. While much focus has been given to Nancy Pelosi and her husband – and indeed, their trading strategy has so far proven successful, as made evident by the returns of a trading bot that copies their investments – Senator Tina Smith has been increasingly in the news in the final months of 2023.

This suspicious congressional trade returned 48% in two months

iShares MSCI Emerging Markets ex China ETF

Tactile Systems

In May 2022, Quiver Quantitative, an alternative data platform catering to retail investors, introduced a trading bot that mimics the stock purchases made by influential US politicians.

This trading bot buys stocks bought by US politicians; Here are its biggest holdings

Largely thanks to the efforts of the online investor community, interesting, suspicious, and conveniently timed trades made by elected officials in the U.S. have come under increased scrutiny in recent years.

Senator up 30% on this year's two most suspicious trades

Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA , Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023.

Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D.

ATLANTA , Nov. 9, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed enrollment in the PERSEVERE clinical trial. The PERSEVERE trial is a prospective, multicenter, non-randomized clinical trial to determine if patients with acute DeBakey Type I aortic dissection can be treated safely and effectively using the AMDS Hybrid Prosthesis.

Artivion Announces Completion of Enrollment in PERSEVERE Trial

Artivion, Inc. (NYSE:AORT ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group Pat Mackin - Chairman, President, and Chief Executive Officer Ashley Lee - Executive Vice President and Chief Financial Officer Conference Call Participants John McAulay - Stifel Shaymus Contorno - Oppenheimer Joseph Stringer - Needham Frank Takkinen - Lake Street Capital Jeffrey Cohen - Ladenburg Thalmann Operator Welcome to the Artivion Third Quarter 2023 Financial Conference Call. At this time, all participants are in a listen-only mode.

Artivion, Inc. (AORT) Q3 2023 Earnings Call Transcript

Third Quarter and Recent Business Highlights: Achieved revenue of $87.9 million in the third quarter of 2023 versus $76.8 million in the third quarter of 2022, an increase of 14% on a GAAP basis and 12% on a non-GAAP constant currency basis Net loss was ($9.8) million or ($0.24) per share; non-GAAP net income was $749,000 or $0.02 per share Non-GAAP adjusted EBITDA increased 34% to $13.9 million in the third quarter of 2023 compared to the third quarter of 2022 Aortic stent graft revenues increased 30% on a GAAP basis and 22% on a non-GAAP constant currency basis in the third quarter of 2023 compared to the third quarter of 2022 On-X revenues increased 14% on a GAAP basis and 13% on a non-GAAP constant currency basis in the third quarter of 2023 compared to the third quarter of 2022 Nearing completion of enrollment in the PERSEVERE clinical trial ATLANTA , Nov. 2, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the third quarter ended September 30, 2023. "Our team delivered across the board in the third quarter, making substantial progress on our commercial, operational, and financial goals and initiatives.

Artivion Reports Third Quarter 2023 Financial Results

ATLANTA , Oct. 19, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2023 financial results will be released on Thursday, November 2, 2023 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results

Artivion has used M&A to reposition itself towards growth opportunities in aortic disease care and heart valves. The company's legacy operations contribute positively to revenue and margins but have limited growth prospects. The success of Artivion's stent-graft business and ongoing clinical trials will determine its future growth potential, as those trials are the gating factor to over $1.2B in potential revenue.

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Late-Breaking Science Presented at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting ATLANTA , Oct. 5, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its On-X Aortic Heart Valve Low INR post-market study presented in a Late-Breaking Science session at the 37th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Vienna, Austria. Real world interim results for all patients confirm that the On-X Aortic Valve remains safe and effective with low-dose warfarin.

Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin

Interim Data Demonstrate Meaningful Reduction of All-Cause Mortality with AMDS ATLANTA , Oct. 5, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today presented interim results from the AMDS PERSEVERE clinical trial in a Late-Breaking Science presentation at the 37th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Vienna, Austria. Dr. Fernando Fleischman, Associate Professor of Clinical Surgery at Keck Hospital of the University of Southern California, presented data from the PERSEVERE US IDE trial as a late-breaking abstract titled, Interim results of AMDS Hybrid Prosthesis in Acute DeBakey Type I Dissection with Malperfusion (Persevere Investigational Device Exemption Study) which includes interim data on 52 study participants at 30-days post-implantation and an additional 8 participants in total follow up (60 total participants).

Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting

ATLANTA, Sept. 26, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deutsche Bank 31st Annual Leveraged Finance Conference on Tuesday, October 3, 2023.

Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference

ATLANTA , Sept. 14, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upcoming Gilmartin Group Emerging Growth Company Showcase on Thursday, September 21, 2023.

Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase

The average of price targets set by Wall Street analysts indicates a potential upside of 44.4% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Artivion (AORT) Could Rally 44.41%: Here's is How to Trade

Alcon Inc. - Registered Shares

Cardinal Health

iRadimed

Penumbra

Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.

News for Artivion Stock (AORT)